HIGHLAND PARK, IL – March 10, 2014 -- UV Flu Technologies, Inc. (OTCBB: UVFT) (OTCQB: UVFT) (the "Company") announced today that Company is planning marketing initiatives for its line of FDA Cleared air purifier products. The company is focused on selling its RX-Air Line to growers and dispensaries for in-house use and distribution through the dispensaries to consumers of the companies UV-400 unit. The company hopes this will help resolve issues with Indoor Air Quality Risks associated with the burgeoning markets for medical and legalized marijuana.
"The health impacts related to the smoking of marijuana or cigarettes are damaging," said Jack Lennon, Founder and head of New Product Development for UV Flu, "I feel this is a product that can help growers and consumers."
"Ironically, although we have sold ViraTech UV-400 air purifiers to companies in the sector, and continue to receive numerous inquiries, the sales have been primarily for the devices ability to remove smoke and odors, while also providing purified air for greenhouses. Air passing through our patented kill chamber exits almost free of impurities, as well as odors, but the catalytic reaction also produces trace amounts of pure water vapor and CO2, elements known to promote plant growth. Our concerns have always been with the higher risk of cancer, respiratory issues and miscarriage, all associated with the direct or second-hand smoke from marijuana sold today, which can be up to 15 times stronger than the drug smoked in the 1960s," said Mr. Lennon. "But we now feel with the unprecedented growth in the sector, we can market to the growers, dispensaries, as well as the consumers, and in the process, help all involved, including adjoining renters who become impacted by the smoke and odors."
"As a veterinarian, particularly one that uses and recommends the ViraTech UV-400 for her clients, the impact of pet owners smoking these new types of marijuana can be particularly acute for both pets and small children," said Dr. Barbara Bodolosky, principal of the Animal Hospital of Sullivan County. "Both pets and small children occupy the space 2 feet above floor level, where the air can be up to 10 times dirtier than that close to the ceiling. The combustion involved with smoking marijuana is much less efficient than cigarettes, causing a much higher concentration of carcinogens sinking to floor levels."
"We have found that the UV-400 can disinfect a typical room within 30 minutes, and animals seem to migrate to rooms where the air purifier is operating. Dogs can exhibit cancer and health issues just like humans, and they can sense areas with clean air to breathe," said Dr. Bodolosky.
"Our Company prides itself on trying to educate the public to the constant introduction of new health risks associated to Indoor Air pollution," said Michael Ross, President of UV Flu. "Through our website, and shows we are attending, such as the AHA Show in Nashville from March 19-22, with thousands of veterinarians and kennel owners attending, and the MedTrade Show in Las Vegas, being held from March 10-12th, with thousands of medical professional attending, we attempt to get the word out. Indoor Air Pollution is the 'Smoking Gun' of many of the health problems we're experiencing today, and UV Flu plans on being at forefront to stopping the spread of airborne sickness and toxins," said Mr. Ross.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com, and click on the 5 minute video describing the ViraTech UV-400™.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer; manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector ($7 billion in 2011). The Company manufactures the ViraTech UV-400™, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com
About RxAir Industries, LLC
RxAir™ is the leading provider of air purification solutions for the medical industry with hundreds of units in waiting rooms to emergency rooms in respected medical facilities nationwide. RxAir™ products remove harmful pathogens from the air in infectious environments for emergency pandemics through isolation rooms and negative pressure rooms. The RxAir™ air purification line is 99.97% efficient, portable, and adaptable, requires zero-maintenance. http://www.rxair.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. Executing the transaction requires further work on structure, management, governance, and other significant matters. Within the next number of months, UV Flu's and RxAir's management will develop detailed plans for the Board's further consideration and final approval.
The completion of the spin-off is subject to a number of conditions, including final approval of the transaction by each Board, favorable tax rulings and or opinions of the transaction to UV Flu and to its shareholders, further due diligence as appropriate, and the filing and effectiveness of appropriate filings with the Securities and Exchange Commission ("SEC"). There can be no assurances given that the separation of UV Flu's business as described in this announcement will occur. UV Flu will provide interim updates as appropriate.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
Michael Ross, President/CEO
Toll-Free: 1-877-358-5545 (FLU-KILL)
Distributor Inquiries, Retail or Internet Inquires:
Please call our Corporate Office at:
SOURCE: UV Flu Technologies, Inc.